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Background: Pediatric erythroderma is a severe cutaneous disorder, which may pose diagnostic and therapeutic
challenges. Psoriasis, ichthyoses, atopy, seborrhoeic dermatitis, pityriasis rubra pilaris, infections, metabolic diseases,
drugs reaction, may cause erythroderma. The therapy should be tailored on each aetiology, if possible. The
biochemical and metabolic imbalance should be corrected, and particular attention should be paid to the
psychosocial behavior often related to this disfiguring disease.
Case presentation: Two 3 year-old Caucasian twins have been suffering from an unmanageable erythroderma
since the age of 8 months. The diagnosis of psoriasis, already remarkably expressed in the father’s family in three
cases of fraternal twins, could be enforced for several points. Major histocompatibility complex, class I, Cw*06 was
detected in both twins; we found no transglutaminase-1, no corneodesmosin, nor any Interleukin-36 receptor
antagonist gene mutations. We performed a cutaneous histology, positive immunostaining for Lympho-epithelial
Kazal-type-related inhibitor, dermoscopy and reflectance confocal microscopy. The twins had previously received
systemic steroids, short cycles of low-dosage ciclosporine, followed by etanercept at the dosage of 0,8 mg/kg,
without reliable results. Cyclosporine was then reconsidered at a dosage of 5 mg/kg/day with close blood monitoring.
After three months of treatment, consistent clearing and significant improvement of their social and psychological
behaviour were achieved. After over one year of continuous therapy with cyclosporine, the twins have still maintained
the result obtained.
Conclusion: Pediatric erythroderma may pose a great challenge as a potentially life-threatening condition causing
extreme distress in children, parents and pediatricians. In young patients it is mandatory to establish correct clinical and
instrumental procedures, possibly supplemented by genetic analyses such as those we required, in order to determine
an effective and safe therapy in terms of cost-benefit and put patients and family in the best condition to perform
common daily activities.
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Children erythroderma may be due to several not related,
inherited or acquired, cutaneous disorders such as psoria-
sis, ichthyoses, pityriasis rubra pilaris, atopy, seborrhoeic
dermatitis, staphylococcal-scalded skin syndrome, infec-
tions, metabolic diseases, drug-induced or unidentified
forms [1-3]. Erythroderma is a severe skin disease - even a* Correspondence: campioneelena@hotmail.com
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unless otherwise stated.possible cause of medical emergency – and a potentially
life threatening disorder, which may offer problems of
misdiagnoses or mismanagements [4-7]. The therapy
should be tailored on each different aetiology, if possible,
and supported by correcting the haematological, biochem-
ical and metabolic imbalance. Moreover, particular atten-
tion should be paid to the psychosocial behavior often
related to this chronic disfiguring skin condition [8].
Herein, we report how a continuous cyclosporine regimentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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atic erythroderma in two three-year-old Caucasian twins.
Case presentation
We visited as consultants two three-year-old Caucasian
twins, sister and brother, suffering from an unmanageable
erythroderma since the age of 8 months, with extreme
distress for parents and pediatricians. At birth, the skin
appearance and the health conditions were referred as
normal in both newborns, who then had a regular growth.
At the time of our visit, a slightly scaling, not exudative,
severely pruritic erythroderma was affecting almost the
entire skin surface with onychodystrophies in both chil-
dren, and ectropion in the twin sister (Figures 1, 2). Note-
worthy, their father and two other twins on the father’s
side also suffer from plaque psoriasis, whereas the father’s
twin sister is affected by psoriatic arthritis. Routine blood
and culture tests did not show haematological, biochem-
ical, metabolic or infective anomalies. MicroscopicFigure 1 Clinical pictures of two 3-year-old twins. Severe pruritic
erythroderma involving the entire skin surface
with onychodistrophies.
Figure 2 Clinical pictures of two 3-year-old twins. Severe pruritic
erythroderma involving the entire skin surface with onychodistrophies.evaluation of Haematoxilyn & Eosin-stained paraffin
sections [9] of skin biopsies performed in both twins
(Figure 3a, b) disclosed marked elongation of rete ridges,
almost absent granular layer and parakeratosis of epider-
mis associated with inflammatory cells with dilated tor-
tuous vessels in the dermal papillae, consistent with the
diagnosis of psoriasis. Positive epidermal immunostaining,
stronger in the upper layers, for Lympho-Epithelial Kazal-
type-related Inhibitor (LEKTI), using polyclonal antibodies
D7-12 and D14-16, excluded the diagnosis of Netherton’s
syndrome. Furthermore, dermoscopy and confocal reflect-
ance microscopy (RCM) were also considered to validate
the diagnosis. Trichoscopy, besides psoriatic hair casts,
did not display any hair shaft anomalies as expected in
Netherton’s syndrome, whereas cutaneous dermoscopy
showed bushy glomerular or dotted vessels, regularly ar-
ranged, in a reddish background covered by white scales
(Figure 4). RCM displayed, starting from the outer layer,
bright nucleated oval cells and dark oval nuclei, described
as clusters of polymorphonuclear leucocytes, reduced
granular layer and preserved the honeycomb pattern of
Figure 3 Microscopic evaluation of Haematoxilyn & Eosin-stained paraffin sections of skin biopsies performed in both twins. a and b
Marked elongation of rete ridges, almost absent granular layer and parakeratosis of epidermis associated with inflammatory cells with dilated
tortuous vessels in the dermal papillae, consistent with the diagnosis of psoriasis.
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were visible as open black and elongated structures, in-
creased in number and diameter. Into the dermal papil-
lary rings, canalicular structures with refractive cells,
corresponding to inflammatory cells infiltration, were
detectable (Figure 6). Genetic blood investigations re-
vealed Major Histocompatibility Complex, class I,
Cw*06 (HLA-Cw*06) expression in both twins and ab-
sence of transglutaminase-1 or corneodesmosin or Inter-
leukin (IL)-36 receptor antagonist gene mutations.
Taken together, the clinical-pathological features, im-
munostaining, dermoscopy and RCM findings, genetic
HLA-Cw*06 testing, with the high prevalence of psoriasis
in the family, were all consistent with the diagnosis of
pediatric psoriatic erythroderma. The twins were previ-
ously treated with emollients, topical and systemic steroids
and short cycles of low-dosage cyclosporine, without any
consistent result. Afterwards, etanercept, a tumor necrosisFigure 4 Dermoscopic features. Dermoscopy showed bushy
glomerular or dotted vessels regularly arranged in a reddish background.factor-alpha receptor inhibitor approved for psoriatic pa-
tients aged 8 years and over, was proposed. After informed
consent as off-label treatment because of their young age,
etanercept was started at a dosage of 0.8 mg/kg subcuta-
neously, once a week. After a short intermission because
of an upper mild respiratory tract viral infection in both
children, etanercept gave ineffective results and was then
stopped after a total of 10 injections. Cyclosporine was
reconsidered but prescribed at a dosage of 5 mg/kg/day as
continuous treatment with close blood monitoring as
scheduled. Acitretin, at a dosage of 0.2 mg/kg per day, was
combined for one month only, because of the risk of bone
anomalies. After one year of continuous treatment,
consistent cutaneous clearing and reduction of pruritus
with significant improvement of their psychological beha-
viour were achieved. Weak redness of the face, moreFigure 5 Confocal reflectance microscopy. Confocal reflectance
microscopy displayed bright nucleated oval cells and dark oval nuclei,
described as microabscesses of leucocytes. At dermo-epidermal
junction we observed black open rings containing refractive cells.
Figure 6 Confocal reflectance microscopy. Confocal reflectance
microscopy displayed bright nucleated oval cells and dark oval nuclei,
described as microabscesses of leucocytes. At dermo-epidermal
junction we observed black open rings containing refractive cells.
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trated mild erythematous areas, without plaque appear-
ance, are still persistent (Figures 7, 8).
Discussion
Erythroderma present since the age of 8 months in frater-
nal young children twins is a rare and severe condition
difficult to be interpreted and treated. As most of the
times, psoriasis is the leading disease among the possible
causes of pediatric erythrodermas [1-3]. This report high-
lights remarkable points: the high prevalence of psoriasis
in the family, the intriguing differential diagnoses andFigure 7 Clinical images during therapy. Residual redness of the face andthe challenging therapeutic options. Familial incidence
is higher in early-onset psoriasis, with 37% of adult-onset
patients and 49% of pediatric-onset patients having first-
degree affected family members [10]. Some studies repor-
ted a familial incidence up to 89% in childhood population
[11]. The positive upper epidermal immunostaining for
protein LEKTI, the absence of transglutaminase-1 or cor-
neodesmosin gene mutations, excluded genodermatoses
such as Netherton’ syndrome, autosomal recessive conge-
nital ichthyoses [12] or inflammatory peeling skin syn-
drome [13], whereas the detection of HLA-Cw*06 in both
twins, as susceptibility locus, was strongly consistent with
an early-onset psoriasis [14], but the clinical picture and
the absence of IL-36 receptor antagonist gene mutations
excluded a deficiency of interleukin 36–receptor antagon-
ist also called DITRA syndrome [15]. Furthermore, their
personal history, the negative blood and culture tests and
the cutaneous histology together with the non-invasive
in vivo methods of investigations could rule out drug-
induced, atopic, infectious or seborrhoeic erythroderma.
Pityriasis rubra pilaris, a close differential diagnosis, could
be excluded due to the lack of some clinical distinctive
features, such as coalescing erythematous perifollicu-
lar papules with follicular plugging, islands of pale skin,
orange-red scaling erythema, palmoplantar yellowish
keratoderma. Furthermore, RCM did not disclose the
appearance described in this disorder of keratinization, in
particular intermingled foci of parakeratosis and orthoker-
atosis in the horny layer and around the follicular infun-
dibula, visible as highly refractive nucleated cells including
bright polygonal structures and areas of cells with bright
borders and dark centers [16,17]. On the other hand, tri-
choscopy, dermoscopy and RCM showed typical features
of psoriasis. In particular, trichoscopy showed psoriatic
hair casts whilst dermoscopy showed bushy glomerular or
dotted vessels regularly arranged in a reddish background
[18,19], whereas RCM, starting from the outer layer,slightly scaling, not infiltrated mild erythematous areas, during treatment.
Figure 8 Clinical images during therapy. Residual redness of the face and slightly scaling, not infiltrated mild erythematous areas, during treatment.
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layer, preserved honeycomb pattern, open black and elon-
gated structures into dermal papillary rings and canalicu-
lar structures with refractive cells [20,21]. Altogether,
clinical-pathological features, genetic and non-invasive
morphological investigations indicated that psoriasis,
already remarkably expressed in the father’s family in
three fraternal twins, was the cause of the pediatric ery-
throderma. Once the disease has been diagnosed, the
treatment is based on the severity of the skin condition
and on the possible presence of joint involvement. Ery-
throderma, together with widespread, refractory plaques,
or generalized pustular psoriasis or psoriatic arthritis, are
the most severe expressions of the disease, which com-
monly require systemic treatment. UV light, systemic reti-
noids, cyclosporine, methotrexate and etanercept improve
the clinical symptoms in childhood psoriasis acting on the
main pathways of the psoriatic lesion [22-24]. From their
past history, no clinical response was achieved with cyclo-
sporine administered at less than 3 mg/kg. This is why
etanercept, the only biologic agent experimented at
the time in Europe in childhood and adolescence, was
firstly prescribed. Beneficial effects are usually expected
already at 4 weeks but, unexpectedly, comparable in-
consistent results were noticed in both our young pa-
tients. The most common trigger factor in childhood
is upper respiratory tract infection, but it is unlikely
that the mild transient infective side effect could have
had a consistent role in maintaining the disease or in re-
ducing the effectiveness of the drug during etanercept
therapy. Cyclosporine, as an immunosuppressant se-
lectively acting on T-cells by calcineurin phosphoryl-
ase inhibition, was the most reliable approach to be
reconsidered but at higher dosages (5 mg/kg/per day) than
those previously experienced as ineffective. The severe
skin condition of the two twins led us to combine one-
month cycle with oral acitretin - in order to enforce theexpected result - but at lower dose to avoid the risk of bone
anomalies.
Conclusions
After one year of continuous cyclosporine treatment we
obtained a substantial improvement consisting in cuta-
neous clearing, significant reduction of pruritus, absence
of side effects, and considerable progresses in social and
psychological behaviour. In young patients affected by
serious skin erythroderma, establishing correct clinical
and instrumental procedures is mandatory. This should
be supplemented by genetic tests such as those we re-
quired to determine the right therapy in terms of cost-
benefit and put patients and families in the best position
to perform common daily activities.
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